Condition: Hemophilia A · Sponsor: Shanghai Xinzhi BioMed Co., Ltd.
This is a multi-center, Phase 1/2/3, single-arm, open-label, single-dose treatment clinical study to evaluate the safety, tolerability and efficacy of BBM-H803 injection in severe Hemophilia A subjects. BBM-H803 is an adeno-associated viral (AAV) vector derived from recombinant DNA techniques to contain an expression cassette of the human factor VIII transgene and raises circulating levels of endogenous FVIII.
This description comes directly from the study's public registry record.
Wenqi Shao, Master · 13636317441 · ra@beliefbiomed.com
Always discuss trial participation with your own doctor first.
| Peking Union Medical College Hospital, Chinese Academy of Medical Sciences | Beijing, Beijing Municipality, China | Recruiting |
| Southern Hospital, Southern Medical University | Guangzhou, Guangdong, China | Recruiting |
| Affiliated Hospital of Guizhou Medical University | Guiyang, Guizhou, China | Recruiting |
| Wuhan Union Hospital Affiliated to Huazhong University of Science and Technology | Wuhan, Hubei, China | Recruiting |
| Xiangya Hospital Central South University | Changsha, Hunan, China | Recruiting |
| The First Affiliated Hospital of Soochow University | Suzhou, Jiangsu, China | Recruiting |
| The Affiliated Hospital of Northwest University Xi'an No.3 Hospital | Xi’an, Shanxi, China | Recruiting |
| Sichuan Provincial People's Hospital | Chengde, Sichuan, China | Recruiting |
| Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College | Tianjin, Tianjin Municipality, China | Recruiting |
| The Second Affiliated Hospital of Kunming Medical University | Kunming, Yunnan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06111638